Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas
详细信息 查看全文
- 作者：Pier Luigi Zinzania ; pierluigi.zinzani@unibo.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Vijayveer Bonthapallyb ; Dirk Huebnerc ; Richard Lutesc ; Andy Chid ; Stefano Pilerie ; f
- 关键词：Adult T-cell leukemia/lymphoma ; Anaplastic large cell lymphoma ; Angioimmunoblastic T-cell lymphoma ; Belinostat ; Brentuximab vedotin ; Peripheral T-cell lymphoma ; Pralatrexate ; Romidepsin
- 刊名：Critical Reviews in Oncology and Hematology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：99
- 期：Complete
- 页码：214-227
- 全文大小：845 K
文摘
- •
About 70% of patients with PTCLs develop relapsed/refractory disease.
- •
Four drugs are specifically approved for use in this setting.
- •
Response rates with pralatrexate, romidepsin, and belinostat range from 25 to 54%.
- •
Brentuximab vedotin achieves responses in 86% of sALCL patients.
- •
Other novel targeted therapies and combinations are showing great promise.